Molecular Imaging

Nuclear imaging, also called molecular imaging, includes positron emission computed tomography (PET) and single photon emission computed tomography (SPECT) imaging. This section includes radiopharmaceuticals and tracers, PET-CT, SPECT-CT, and PET-MRI. Molecular imaging includes the field of nuclear medicine, which uses very small amounts of radioactive materials, or radiopharmaceuticals, to diagnose and treat disease.

NorthStar’s high purity non-carrier-added (n.c.a.) Ac-225 to be used in advancing Nucleus’ partners radioligand therapies to treat cancer
News | Molecular Imaging
NorthStar Medical Radioisotopes Announces Supply Agreement with Nucleus RadioPharma for Alpha-emitting Therapeutic Radioisotope Actinium-225 (Ac-225)

July 5, 2023 — NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and ...

Time July 05, 2023
arrow
City of Hope researchers establish foundation to expand SCINTIX therapy using a prostate cancer-specific PET radiotracer
News | Prostate Cancer
RefleXion Highlights Clinical Study Results for Future Prostate Cancer Treatment

July 3, 2023 — RefleXion Medical, Inc., a therapeutic oncology company, today announced that results of a prospective ...

Time July 03, 2023
arrow
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) hosted nearly 8,000 physicians, technologists, pharmacists, laboratory professionals, scientists and others at its 2023 Annual Meeting, themed “Eye on the Patient,” held in Chicago, Illinois.
News | SNMMI
SNMMI Keeps “Eye on the Patient” at 2023 Annual Meeting

June 30, 2023 — The Society of Nuclear Medicine and Molecular Imaging (SNMMI) hosted nearly 8,000 physicians ...

Time June 30, 2023
arrow
News | SNMMI
Research Showing Genomics- and Image-Guided Subtyping Refines Characterization of Alzheimer’s Disease Presented at SNMMI 2023

June 29, 2023 — Research presented at the 2023 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging ...

Time June 29, 2023
arrow
News | SNMMI
Prostate Cancer Treatment Study at SNMMI 2023 Finds Improved Patient Outcomes with Personalized Dosing

June 29, 2023 — A study presented this week during the 2023 Society of Nuclear Medicine and Molecular Imaging (SNMMI) ...

Time June 29, 2023
arrow
Molecular imaging with 18F-flubatine PET/MRI has shown that neuroreceptors in the brains of individuals with obesity respond differently to food cues than those in normal-weight individuals, making the neuroreceptors a prime target for obesity treatments and therapy
News | SNMMI
Molecular Imaging Identifies Brain Changes in Response to Food Cues; Offers Insight into Obesity Interventions

June 28, 2023 — Molecular imaging with 18F-flubatine PET/MRI has shown that neuroreceptors in the brains of individuals ...

Time June 28, 2023
arrow
A newly discovered radionuclide-based agent (CB-2PA-NT) has been shown to have high tumor uptake, sustained tumor retention, and high contrast in preclinical models, making it a prime candidate for a novel theranostics approach
News | SNMMI
Novel Theranostic Agent Targets Multiple Cancer Types

June 28, 2023 — A newly discovered radionuclide-based agent (CB-2PA-NT) has been shown to have high tumor uptake ...

Time June 28, 2023
arrow
A novel PET perfusion radiotracer, 18F-flurpiridaz, can diagnose coronary artery disease (CAD) in obese patients with a higher sensitivity and specificity compared to 99Tc-SPECT myocardial perfusion imaging (MPI)
News | SNMMI
Novel Radiotracer Demonstrates High Diagnostic Efficacy for Obese Patients with Coronary Artery Disease

June 28, 2023 — A novel PET perfusion radiotracer, 18F-flurpiridaz, can diagnose coronary artery disease (CAD) in obese ...

Time June 28, 2023
arrow
News | SNMMI
Society of Nuclear Medicine and Molecular Imaging Names Helen Nadel, MD, FRCPC, of Stanford, as President, Announces New Officers at SNMMI 2023 Annual Meeting

June 27, 2023 — Helen Nadel, MD, FRCPC, director of pediatric nuclear medicine at Lucile Packard Children’s Hospital at ...

Time June 27, 2023
arrow
Contrast-enhanced mammography (CEM) is an emerging modality combining digital mammography with the administration of a contrast agent
News | Contrast Media
FDA approves Bayer’s Ultravist (iopromide) Injection for Contrast-enhanced Mammography

June 26, 2023 — Bayer announced that Ultravist (iopromide)-300, -370, its iodine-based contrast agent, has been approved ...

Time June 26, 2023
arrow
Nizar A. Mullani, one of the pioneers of the first positron emission tomography (PET) prototype, has been named as this year’s recipient of the Georg Charles de Hevesy Nuclear Pioneer Award.
News | SNMMI
Nizar A. Mullani Receives SNMMI 2023 Georg Charles de Hevesy Nuclear Pioneer Award

June 26, 2023 — Nizar A. Mullani, one of the pioneers of the first positron emission tomography (PET) prototype, has ...

Time June 26, 2023
arrow
Umar Mahmood, MD, PhD, chief of Nuclear Medicine and Molecular Imaging, director of the Center for Precision Imaging, and associate chair for imaging sciences in the Department of Radiology at Massachusetts General Hospital and professor of radiology at Harvard Medical School in Boston, Massachusetts, has been named as the first recipient of the new Minoshima-Pappas Transformational Leadership Award.
News | SNMMI
Umar Mahmood, MD, PhD, Receives First Annual SNMMI Minoshima-Pappas Transformational Leadership Award

June 26, 2023 — Umar Mahmood, MD, PhD, chief of Nuclear Medicine and Molecular Imaging, director of the Center for ...

Time June 26, 2023
arrow
News | SNMMI
Study on Value of 68Ga-FAPI PET/CT Imaging for Evaluation of Disease Activity in Rheumatoid Arthritis presented during SNMMI 2023

June 26, 2023 — PET imaging with 68Ga-FAPI offers a feasible, reliable, and reproducible method for evaluating disease ...

Time June 26, 2023
arrow
During its 2023 Annual Meeting, the Image of the Year was selected by the Society of Nuclear Medicine and Molecular Imaging (SNMMI), and represents research presented which reports on the ability of a novel theranostic pair to successfully detect metastatic pancreatic cancer and provide a means of selecting appropriate treatments.
News | SNMMI
Image of the Year and Research Announced at SNMMI 2023 on Theranostic Pair for Early Detection and Effective Treatment of Pancreatic Cancer

June 26, 2023 — A first-in-human evaluation of the novel theranostic pair 68Ga-DOTA-5G / 177Lu-DOTA-ABM-5G has confirmed ...

Time June 26, 2023
arrow
A new PET radiotracer that visualizes the enzyme primarily responsible for metabolic cholesterol degradation in the brain has been successfully validated
News | SNMMI
Translational PET Tracer Visualizes Brain Cholesterol Metabolism

June 25, 2023 — A new PET radiotracer that visualizes the enzyme primarily responsible for metabolic cholesterol ...

Time June 25, 2023
arrow
Julie Dawn Bolin, MS, CNMT, program director of nuclear medicine technology at GateWay Community College in Phoenix, Arizona, and nuclear medicine technologist at Banner Staffing Services in Tucson, Arizona, has been elected 2023-24 president-elect for the Society of Nuclear Medicine and Molecular Imaging Technologist Section (SNMMI-TS)
News | SNMMI
SNMMI Announces Julie Dawn Bolin, MS, CNMT, as President-Elect of the Technologist Section During 2023 Annual Meeting

June 25, 2023 — Julie Dawn Bolin, MS, CNMT, program director of nuclear medicine technology at GateWay Community College ...

Time June 25, 2023
arrow
News | SNMMI
Ultra-High Resolution Brain PET Scanner Visualizes and Quantifies Brainstem Nuclei for the First Time

June 24, 2023 — A new ultra-high resolution (UHR) brain PET scanner may have the ability to characterize previously ...

Time June 24, 2023
arrow
 A newly developed technology called “augmented whole-body scanning via magnifying PET” (AWSM-PET) has been shown to enhance the image resolution and system sensitivity of clinical whole-body PET/CT imaging.
News | SNMMI
New Whole-Body PET Technology Offers Cost-Effective Solution to Improve Image Resolution and Sensitivity

June 24, 2023 — A newly developed technology called “augmented whole-body scanning via magnifying PET” (AWSM-PET) has ...

Time June 24, 2023
arrow
Cardinal Health Nuclear & Precision Health Solutions (NPHS) (Booth #2041) will feature information on radiotherapies and theranostics readiness at the Society of Nuclear Medicine & Molecular Imaging (SNMMI) 2023 Annual Meeting.
News | SNMMI
Cardinal Health Highlights Nuctrac Theranostic Module, Theranostics Readiness at SNMMI 2023

June 23, 2023 — Cardinal Health Nuclear & Precision Health Solutions (NPHS) (Booth #2041) will feature information on ...

Time June 23, 2023
arrow
Therapeutically equivalent and fully substitutable to Kinevac (Sincalide for Injection) formulated, filled and packaged in the United States provides health care facilities with choice and value
News | Contrast Media
Fresenius Kabi Broadens Radiology Portfolio with its First-to-Market Authorized Generic, Sincalide for Injection

June 21, 2023 — Fresenius Kabi, a leading provider of injectable medicines, announced today it has launched the ...

Time June 21, 2023
arrow
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now